BlossomHill Therapeutics Announces Updated Phase 1/2 SOLARA Data On BH-30643 In EGFR-Mutant NSCLC With Secondary Resistance Mutations To Be Presented September 15 At World Conference On Lung Cancer

뉴스 본문을 불러오고 있어요.

BlossomHill Therapeutics Announces Updated Phase 1/2 SOLARA Data On BH-30643 In EGFR-Mutant NSCLC With Secondary Resistance Mutations To Be Presented September 15 At World Conference On Lung Cancer | 웨이프 WAPE

BlossomHill Therapeutics Announces Updated Phase 1/2 SOLARA Data On BH-30643 In EGFR-Mutant NSCLC With Secondary Resistance Mutations To Be Presented September 15 At World Conference On Lung Cancer

기사 요약

관련 종목

댓글 —